期刊
CANCER AND METASTASIS REVIEWS
卷 30, 期 1, 页码 19-26出版社
SPRINGER
DOI: 10.1007/s10555-011-9291-2
关键词
Sunitinib; Angiogenesis; IGF-1R; Sorafenib; Bevacizumab; Carcinoid tumors; Targeted therapy; Orphan disease; Pancreatic neuroendocrine tumors
类别
资金
- Pfizer Spain
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) show limited sensitivity to cytotoxic agents, requiring the search for novel therapies. Recently, data from a phase III trial demonstrated that sunitinib produces a clinically significant improvement in progression-free survival in patients with unresectable, advanced, or metastatic GEP-NETs. Based on this finding, sunitinib became the first targeted drug approved for the treatment of GEP-NETs, paving the way for the approval of other anticancer agents in this drug-orphan disease. To date, results of trials involving other multitargeted tyrosine kinase inhibitors, such as sorafenib, the monoclonal antibody bevacizumab, and insulin-like growth factor 1 receptor inhibitors, have also shown promising results, and some are already being studied in phase III trials. This review updates the results of ongoing trials using inhibitors of growth factors and tyrosine kinase receptors involved in the carcinogenesis of GEP-NETs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据